79 related articles for article (PubMed ID: 6388575)
1. Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro.
Dugue B; Paoletti C; Meunier B
Biochem Biophys Res Commun; 1984 Oct; 124(2):416-22. PubMed ID: 6388575
[TBL] [Abstract][Full Text] [Related]
2. Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.
Bernadou J; Meunier B; Meunier G; Auclair C; Paoletti C
Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1297-301. PubMed ID: 6584882
[TBL] [Abstract][Full Text] [Related]
3. Peroxidase-catalysed oxidation of N2,N6-dimethyl-9-hydroxyellipticinium acetate. Evidence for the formation of an electrophilic quinone-iminium derivative.
Meunier G; Bernadou J; Meunier B
Biochem Pharmacol; 1987 Aug; 36(16):2599-604. PubMed ID: 3606658
[TBL] [Abstract][Full Text] [Related]
4. Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture.
Dugue B; Auclair C; Meunier B
Cancer Res; 1986 Aug; 46(8):3828-33. PubMed ID: 2425935
[TBL] [Abstract][Full Text] [Related]
5. Peroxidase-catalyzed covalent binding of the antitumor drug N2-methyl-9-hydroxyellipticinium to DNA in vitro.
Auclair C; Dugué B; Meunier B; Paoletti C
Biochemistry; 1986 Mar; 25(6):1240-5. PubMed ID: 3964674
[TBL] [Abstract][Full Text] [Related]
6. Evidence for electrophilic properties of N2-methyl-9-hydroxy ellipticinium acetate (Celiptium) from human biliary metabolites.
Bernadou J; Monsarrat B; Roche H; Armand JP; Paoletti C; Meunier B
Cancer Chemother Pharmacol; 1985; 15(1):63-5. PubMed ID: 4006051
[TBL] [Abstract][Full Text] [Related]
7. Human and rat urinary metabolites of the antitumor drug Celiptium (N2-methyl-9-hydroxyellipticinium acetate, NSC 264137). Identification of cysteine conjugates supporting the "biooxidative alkylation" hypothesis.
Monsarrat B; Maftouh M; Meunier G; Dugué B; Bernadou J; Armand JP; Picard-Fraire C; Meunier B; Paoletti C
Biochem Pharmacol; 1983 Dec; 32(24):3887-90. PubMed ID: 6661266
[No Abstract] [Full Text] [Related]
8. Metabolism of the anti-tumour drugs N2-methyl-9-hydroxyellipticinium acetate (NSC 264137) and N2-methyl-9-hydroxyolivacinium acetate in the rat: preliminary identification of biliary 9-(O)-glucuronide and 10-(S)-glutathione conjugates.
Maftouh M; Meunier G; Dugue B; Monsarrat B; Meunier B; Paoletti C
Xenobiotica; 1983 May; 13(5):303-10. PubMed ID: 6636827
[TBL] [Abstract][Full Text] [Related]
9. Peroxidase-catalyzed O-demethylation reactions. Quinone-imine formation from 9-methoxyellipticine derivatives.
Meunier G; Meunier B
J Biol Chem; 1985 Sep; 260(19):10576-82. PubMed ID: 4030757
[TBL] [Abstract][Full Text] [Related]
10. The rat biliary and urinary metabolism of the N6-methylated derivative of elliptinium acetate, and antitumor agent.
Braham Y; Meunier G; Meunier B
Drug Metab Dispos; 1988; 16(2):316-21. PubMed ID: 2898353
[TBL] [Abstract][Full Text] [Related]
11. Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile.
Maftouh M; Monsarrat B; Rao RC; Meunier B; Paoletti C
Drug Metab Dispos; 1984; 12(1):111-9. PubMed ID: 6141901
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of drug-DNA interactions: a comparative temperature jump study of ellipticinium and 9-hydroxy ellipticinium.
Schwaller MA; Aubard J; Dodin G
J Biomol Struct Dyn; 1988 Dec; 6(3):443-58. PubMed ID: 3271531
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J
Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658
[TBL] [Abstract][Full Text] [Related]
14. omicron-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.
Bernadou J; Meunier G; Paoletti C; Meunier B
J Med Chem; 1983 Apr; 26(4):574-9. PubMed ID: 6834391
[TBL] [Abstract][Full Text] [Related]
15. 2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study.
Tura S; Mandelli F; Mazza P; Cimino G; Anselmo AP; Amadori S
Chemioterapia; 1984 Apr; 3(2):79-82. PubMed ID: 6532540
[TBL] [Abstract][Full Text] [Related]
16. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].
Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025
[TBL] [Abstract][Full Text] [Related]
17. Attempts to target antitumor drugs toward opioid receptor-rich mouse tumor cells with enkephalin-ellipticinium conjugates.
Rigaudy P; Charcosset JY; Garbay-Jaureguiberry C; Jacquemin-Sablon A; Roques BP
Cancer Res; 1989 Apr; 49(7):1836-42. PubMed ID: 2538235
[TBL] [Abstract][Full Text] [Related]
18. A revised structure of the antitumor drug elliptinium--amino(acid) adducts.
Gouyette A; Auclair C; Paoletti C
Biochem Biophys Res Commun; 1985 Sep; 131(2):614-9. PubMed ID: 2996516
[TBL] [Abstract][Full Text] [Related]
19. Peroxidase-catalysed covalent binding of the antitumor drug 2N-methyl-9-hydroxy-ellipticine to proteins.
Auclair C; Meunier B; Paoletti C
Biochem Pharmacol; 1983 Dec; 32(24):3883-6. PubMed ID: 6661265
[No Abstract] [Full Text] [Related]
20. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl.
Auclair C; Pierre A; Voisin E; Pepin O; Cros S; Colas C; Saucier JM; Verschuere B; Gros P; Paoletti C
Cancer Res; 1987 Dec; 47(23):6254-61. PubMed ID: 3677074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
